Literature DB >> 6638670

In vivo bronchodilator activity of vasoactive intestinal peptide in the cat.

L Diamond, J L Szarek, M N Gillespie, R J Altiere.   

Abstract

Vasoactive intestinal peptide (VIP) is an octacosapeptide that occurs widely in the animal kingdom, is distributed in many organs and tissues, and has a broad range of biologic actions. We evaluated the ability of VIP to produce bronchodilation in anesthetized, mechanically ventilated, atropinized, closed chest cats. Boluses of VIP injected intravenously (0.1 to 10 micrograms X kg-1) reversed in a dose-dependent manner the increase in lung resistance (RL) and the decrease in dynamic lung compliance (Cdyn) induced by an intravenously administered infusion of 5-hydroxytryptamine (5HT) (5 to 30 micrograms X kg-1 X min-1). Distribution of bronchodilator activity was assessed by using RL as an index of central airways caliber and dynamic elastance (Edyn; the inverse of Cdyn) as an index of tone in peripheral airways and lung parenchyma. Although all levels of the tracheobronchial tree responded to VIP, the predominant site of action appeared to be in central airways. A similar distribution and magnitude of relaxant effects were observed after the intravenous administration of prostaglandin E2 (PGE2) (0.1 to 10 micrograms X kg-1). Prostaglandin E2 also was effective in reversing 5HT-induced bronchoconstriction when given by ultrasonic nebulization, whereas VIP was not. Bronchodilation mediated by VIP persisted after pretreatment with indomethacin or propranolol. We conclude that VIP is a potent relaxant of feline airways smooth muscle in vivo and that this effect of the peptide occurs independent of prostaglandin production or beta adrenergic receptor activation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6638670     DOI: 10.1164/arrd.1983.128.5.827

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  15 in total

1.  Distribution and co-localization of immunoreactive helospectin with vasoactive intestinal polypeptide and peptide histidine methionine in human nasal mucosa, soft palate and larynx.

Authors:  C E Hauser-Kronberger; G W Hacker; F Sundler; J Thurner; K Albegger
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

2.  Effects of epithelium removal on relaxation of airway smooth muscle induced by vasoactive intestinal peptide and electrical field stimulation.

Authors:  S G Farmer; J Togo
Journal:  Br J Pharmacol       Date:  1990-05       Impact factor: 8.739

3.  Regulatory peptides in the respiratory system.

Authors:  P J Barnes
Journal:  Experientia       Date:  1987-07-15

4.  Relaxation of cat tracheobronchial and pulmonary arterial smooth muscle by vasoactive intestinal peptide: lack of influence by peptidase inhibitors.

Authors:  R J Altiere; L Diamond
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

Review 5.  Vasoactive intestinal peptide.

Authors:  S I Said
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

6.  Cigarette smoke, nicotine and capsaicin aerosol-induced vasodilatation in pig respiratory mucosa.

Authors:  R Matran; K Alving; J M Lundberg
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

7.  The third nervous system in the lung: physiology and clinical perspectives.

Authors:  P J Barnes
Journal:  Thorax       Date:  1984-08       Impact factor: 9.139

8.  Effect of passive sensitization on the mechanical activity of human isolated bronchial smooth muscle induced by substance P, neurokinin A and VIP.

Authors:  A Ben-Jebria; R Marthan; M Rossetti; J P Savineau
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

9.  VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.

Authors:  H Aizawa; H Inoue; M Shigyo; S Takata; H Koto; K Matsumoto; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

10.  The effect of vasoactive intestinal peptide on smooth muscle tone and mucus secretion from the ferret trachea.

Authors:  S E Webber; J G Widdicombe
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.